
Opinion|Videos|August 15, 2023
Triplet Regimens for First-Line Advanced Renal Cell Carcinoma
Author(s)Rana R. McKay, MD
Discussion on triplet therapy regimens in advanced RCC and how progressing therapeutic studies can impact its future use.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5









































